lapatinib
E902877
EGFR inhibitor
HER2 inhibitor
antineoplastic agent
oral anticancer agent
protein kinase inhibitor
small-molecule drug
tyrosine kinase inhibitor
Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
All labels observed (2)
| Label | Occurrences |
|---|---|
| lapatinib canonical | 3 |
| lapatinib ditosylate | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074260 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: lapatinib Context triple: [HER2 receptor, targetOfDrug, lapatinib]
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
C.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
D.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: lapatinib Target entity description: Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
C.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
D.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
EGFR inhibitor
ⓘ
HER2 inhibitor ⓘ antineoplastic agent ⓘ oral anticancer agent ⓘ protein kinase inhibitor ⓘ small-molecule drug ⓘ tyrosine kinase inhibitor ⓘ |
| bindsTo |
ATP-binding site of EGFR
ⓘ
ATP-binding site of HER2 ⓘ |
| developedBy | GlaxoSmithKline ⓘ |
| hasApprovalBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| hasATCCode | L01EB07 ⓘ |
| hasBioavailability | low to moderate oral bioavailability ⓘ |
| hasBoxedWarningFor | hepatotoxicity ⓘ |
| hasCASNumber | 231277-92-2 ⓘ |
| hasChemicalFormula | C29H26ClFN4O4S ⓘ |
| hasCommonAdverseEffect |
diarrhea
ⓘ
fatigue ⓘ nausea ⓘ rash ⓘ |
| hasEliminationHalfLife | approximately 24 hours ⓘ |
| hasMolecularWeight | 581.06 g/mol ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
cardiac dysfunction
ⓘ
hepatotoxicity ⓘ |
| hasTradeName |
Tykerb
ⓘ
Tyverb ⓘ |
| inhibits |
autophosphorylation of EGFR
ⓘ
autophosphorylation of HER2 ⓘ |
| isAdministeredAs |
lapatinib ditosylate
ⓘ
linked to:
lapatinib
|
| isHighlyProteinBound | true ⓘ |
| isMetabolizedBy |
CYP2C19
ⓘ
CYP2C8 ⓘ CYP3A4 ⓘ CYP3A5 ⓘ |
| isPregnancyCategory | D (US, historical classification) ⓘ |
| isSubstrateOf | P-glycoprotein ⓘ |
| mechanismOfAction | reversible inhibition of HER2 and EGFR tyrosine kinases ⓘ |
| oftenUsedWith |
capecitabine
ⓘ
linked to:
Xeloda
letrozole ⓘ |
| reduces |
downstream MAPK signaling
ⓘ
downstream PI3K/AKT signaling ⓘ |
| targets |
EGFR
ⓘ
ERBB1 ⓘ
linked to:
EGFR
ERBB2 ⓘ HER2 ⓘ
linked to:
ERBB2
|
| usedFor |
HER2-positive breast cancer
ⓘ
advanced breast cancer ⓘ metastatic breast cancer ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: lapatinib Description of subject: Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: lapatinib